text_1: Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.
text_2: Through type I IFN signaling, AZA increases the numbers of CD45+ immune cells and the percentage of active CD8+ T and natural killer (NK) cells in the tumor microenvironment, while reducing tumor burden and extending survival.